Lenstec announced that it has completed its FDA trial for the SBL-3 IOL (Segmented Bifocal Lens), an asymmetric multifocal refractive IOL designed to provide patients with superior near, intermediate, and distance vision. It also offers improved contrast sensitivity and minimizes halos and glare (dsyphotopsias) commonly associated with other traditional multifocal-presbyopia correcting IOLs, according to a company news release.
“This is an exciting milestone for Lenstec and brings us closer to completing regulatory approval in the US,” Lenstec’s VP Sales and Marketing Gary Lattanzio said in the news release.
Utilizing segmented bi-aspheric optic technology, the SBL-3 has two refracting surfaces to capture light on different parts of the retina for near and distance vision.
Lenstec’s patented 4-point fixation shape design, and 0.25 diopter power increments enable superior effective lens positioning and visual outcomes.
Upon successful completions of these trials and final FDA approval, the SBL-3 would be the first segmented bifocal IOL in the US market.
Lenstec Completes FDA Trials of SBL-3